Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 5/20 | 0.62 |
| ▸ | AR | P10275 | 2/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 3/20 | 0.50 |
| ▸ | PGR | P06401 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NPY1R | P25929 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11486638 | 0.91 | TNKS (0.55) | TNKSMAOBARALOX5CA1 | |
| SCHEMBL11486644 | 0.91 | TNKS (0.55) | TNKSMAOBARALOX5CA1 | |
| SCHEMBL4659168 | 0.83 | MAOB (0.78) | MAOBALOX5CA1CA2CA9 | |
| SCHEMBL3537582 | 0.81 | MAOB (0.58) | TNKSMAOBARCYP2A6MAOA | |
| SCHEMBL8187479 | 0.80 | TNKS (0.63) | TNKSARCA1CA2CA9 | |
| SCHEMBL5768216 | 0.80 | MAOB (0.72) | TNKSMAOBARALOX5CA1 | |
| SCHEMBL31105656 | 0.79 | MAOB (0.71) | TNKSMAOBARALOX5CA1 | |
| SCHEMBL731363 | 0.79 | MAOB (0.71) | TNKSMAOBARALOX5CA1 | |
| SCHEMBL11500108 | 0.78 | MAOB (0.43) | TNKSMAOBARALOX5CA1 | |
| SCHEMBL11500109 | 0.78 | MAOB (0.43) | TNKSMAOBARALOX5CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070782-A1 | METHOD FOR SYNTHESIZING BORONATE ESTER COMPOUND, SODIUM SALT OF BORONATE ESTER COMPOUND, AND METHOD FOR SYNTHESIZING THE SAME | KOBELCO ECO-SOLUTIONS CO., LTD. (JP) | 2021-03-11 | — | — | US | disclosed |
| EP-3741764-A1 | SYNTHESIS METHOD FOR BORONIC ACID ESTER COMPOUND, AND SODIUM SALT OF BORONIC ACID ESTER COMPOUND AND SYNTHESIS METHOD THEREFOR | Kobelco Eco-Solutions Co., Ltd (JP) | 2020-11-25 | — | — | EP | disclosed |
| US-7473786-B1 | Methods and systems for preparing fused heterocyclic compounds using copper(I) catalysts | UNIVERSITY OF MASSACHUSETTS (US) | 2009-01-06 | — | — | US | disclosed |
| US-7473786-B1 | Methods and systems for preparing fused heterocyclic compounds using copper(I) catalysts | UNIVERSITY OF MASSACHUSETTS (US) | 2009-01-06 | — | — | US | disclosed |
| US-7473786-B1 | Methods and systems for preparing fused heterocyclic compounds using copper(I) catalysts | UNIVERSITY OF MASSACHUSETTS (US) | 2009-01-06 | — | — | US | disclosed |
| WO-2000078726-A1 | IMIDAZOLINE DERIVATIVES FOR THE TREATMENT OF DIABETES, ESPECIALLY TYPE II DIABETES | ELI LILLY AND COMPANY (US) | 2000-12-28 | — | — | WO | disclosed |
| US-4039555-A | Benzofuran derivatives, process for preparing them and their use as optical brighteners | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-08-02 | — | — | US | disclosed |
| US-3931215-A | OPTICAL BRIGHTENERS | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070782-A1 | METHOD FOR SYNTHESIZING BORONATE ESTER COMPOUND, SODIUM SALT OF BORONATE ESTER COMPOUND, AND METHOD FOR SYNTHESIZING THE SAME | BRSK1, BRSK2, BRI3BP | TNKS 3192/4885MAOB 1343/4885AR 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.